Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing.
The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen Horowitz, joined the company’s board of directors.
Led by Eric Kelsic, PhD, founder and CEO, Dyno Therapeutics is advancing the CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors, broadening the functionality and enhancing the therapeutic impact of gene therapies developed by its biopharmaceutical partners.
The company intends to use the capital to expand its CapsidMap™ platform. Proceeds from the financing will accelerate building Dyno’s CapsidMap platform to design improved vectors targeting liver, muscle, eye and central nervous system (CNS) disease, as well as growing into new areas of lung, heart and kidney disease. The company will also use the proceeds to support its multiple partnership efforts with gene therapy biopharmaceutical companies by growing its operations, intellectual property, business development and partner success teams. This expansion augments Dyno’s existing partnerships to develop AAV vectors for Novartis, Sarepta and Roche and builds capacity to work with many additional partners. The financing will enable the company to increase its employee base across science, machine learning and business functions.